Silence Therapeutics To Receive $2M Research Milestone Payment From Hansoh Pharma, Following The Achievement Of A Second Undisclosed Milestone Related To The First Target Under The Collaboration
Silence Therapeutics To Receive $2M Research Milestone Payment From Hansoh Pharma, Following The Achievement Of A Second Undisclosed Milestone Related To The First Target Under The Collaboration
翰森制药将向Silence Therapeutics支付200万美元的研究里程碑费用，以此庆祝在合作的第一目标下达成第二个未公开里程碑。
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision engineered medicines, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited ("Hansoh") following the achievement of a second undisclosed milestone related to the first target under the collaboration
Silence Therapeutics plc，纳斯达克：SLN（以下简称“Silence”或“公司”），一家经验丰富且创新的生物技术公司，致力于通过精密设计的药物来沉默疾病，改善人们的生活。今天宣布，在与汉赛药业集团有限公司（以下简称“汉赛药业”）合作下，公司完成了与其合作的第一个目标的第二项不公开里程碑，将收到200万美元的现金支付。